Neuroprotective Strategies in Neural Grafting
The survival of neural grafts is dependent on a multitude of both donor-and host-related conditions. The importance of several of these factors, such as anatomical specificity and age of the donor tissue, surgical technique, immunology, presence of growth factors, and so on, are described in other chapters of this book. The significance of obtaining good survival of neural transplants from a limited source of donor tissue is particularly pertinent when transplanting immature dopamine (DA) neurons. Clinical trials with human embryonic nigral grafts in Parkinson’s disease have clearly shown that the implants can provide major symptomatic relief in the patients (Kordower et al., 1996 , Kordower et al., 1998 ; Lindvall, 1997 ; Tabbal et al., 1998 ). The success of this therapy is intimately coupled to a significant restoration of striatal DA levels, as evidenced by positron emission tomography scans, and this can only be achieved when there is good transplant survival. Also, in experimental animals with lesions of the nigrostriatal pathway, a clear correlation between the number of surviving dopaminergic (DA-ergic) neurons in grafts and the degree of behavioral restoration has been found (for review, see Brundin et al., 1994 ). Studies in experimental animals indicate that survival rate of transplanted DA neurons is typically approx 5–15% (Table 1 ). Neuropathological data from two human transplant cases suggest that the survival rate of grafted DA-ergic neurons in Parkinson’s disease patients is in the lower range of this interval (Kordower et al., 1996 ,Kordower et al., 1998 ). Table 1 Attempts at Enhancing Survival of Grafted Rat DA-ergic Neurons by Different Treatments
Control (% Survival) | Treatment (% Survival) | Notes | |
---|---|---|---|
GDNF | |||
Rosenblad et al., 1996 a | 9.7 | 37.4 | |
Sinclair et al., 1996 b | 0.7 | 8.1 | |
Sinclair et al., 1996 a | 1.0 | 13.0 | |
Granholm et al., 1997 | 2.5-fold increase | No absolute quantification | |
Apostolides et al., 1997 a | 2.4 | 1.6 | Fresh |
Apostolides et al., 1997 a | 2.6 | 3.4 | Hibernated 6 d |
Mehtaetal., 1998 a | 1.6 | 2.0 | Hibernated 6 d |
Sautter et al., 1998 b | 5.1 | 12.9 | |
Yureketal., 1998 b | 1.9 | 5.8 | |
bFGF | |||
Mayer et al., 1993 a | 0.9 | 1.6 | 3-wk survival |
Mayer et al., 1993 b | 1.0 | 2.7 | 9-wk survival |
Takayama et al., 1995 a | 6.3 | 87.5 | |
Takayama et al., 1995 b | 1.5 | 20.0 | |
Zeng et al., 1996 a | 10.9 | 25.0 | |
GDNF + bFGF + IGF | |||
Zawada et al., 1998 | 8.2 | 12.7 | 24-h survival |
Zawada et al., 1998 | 4.1 | 6.6 | 7-d survival |
Lazaroids | |||
Nakao et al., 1994 b | 15.7 | 41.4 | |
Grasbon-Frodl et al., 1996 b | b 6.5 | 14.0 | Hibernated 8 d |
Bj�rklund et al., 1997 b | 0.9 | 2.3 | Solid grafts in anterior eye chamber |
Karlsson et al., 1999 b | 6.4 | 10.9 | |
Calcium antagonists Finger and Dunnett, 1989 | Increased graft volume | Dopamine neurons not quantified | |
Kaminski Schierle et al., 1999 b | 8.2 | 21.5 | |
Caspase inhibitors Schierle et al., 1999 b | 10 | 36 |
Figures are either those stated by the respective authors or have been computed based on data presented in the publication based on one of the two following assumptions: a Approximately 8% of the cells in dissected embryonic rat mesencephalic tissue are DA-ergic. These assumptions imply that there are around 400,000 cells obtained from each dissected ventral mesencephalon. b There are approx 35,000 DA neurons in one rat embryonic mesencephalon.
- The 3xTg-AD Mouse Model: Reproducing and Modulating Plaque and Tangle Pathology
- Measuring Endocrine (Cortisol) Responses of Zebrafish to Stress
- Generation of Primary Astrocyte Cultures Devoid of Contaminating Microglia
- Monitoring Calcium Levels With Genetically Encoded Indicators
- Recording from Macropatches
- Detection of Neuropeptides by Immunocytochemistry
- Brain Capillaries: Cell Culture of Capillary Endothelium Derived from Cerebral Microvessels
- Animal Models of Mental Retardation
- Statistics in Experimental Stroke Research: From Sample Size Calculation to Data Description and Significance Testing
- Development of Antibodies to Adrenergic Receptors